These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11102283)

  • 1. Biotechnology: alternatives to human plasma-derived therapeutic proteins.
    Lynch TJ
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):669-88. PubMed ID: 11102283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recombinant plasma proteins for therapeutic use--status and developmental trends].
    Storch H
    Beitr Infusionsther; 1993; 31():31-7. PubMed ID: 7693261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hemophilias--gene therapy to come?
    Vajó Z; Sréter L
    Acta Physiol Hung; 1996; 84(2):191-8. PubMed ID: 9046365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New high-technology products for the treatment of haemophilia.
    Pipe SW; Saint-Remy JM; Walsh CE
    Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII.
    Farrugia A
    Australas Biotechnol; 1993; 3(1):16-20. PubMed ID: 7763537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic applications of genetic engineering].
    Descamps JL
    Ann Pharm Fr; 1994; 52(6):294-302. PubMed ID: 7864529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical importance of human plasma proteins and their future development].
    Schwick HG
    Beitr Infusionsther; 1991; 28():115-23. PubMed ID: 1725608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant clotting factors.
    Pipe SW
    Thromb Haemost; 2008 May; 99(5):840-50. PubMed ID: 18449413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma-derived biological medicines used to promote haemostasis.
    Ofosu FA; Freedman J; Semple JW
    Thromb Haemost; 2008 May; 99(5):851-62. PubMed ID: 18449414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharmaceuticals derived from genetically modified plants.
    Goldstein DA; Thomas JA
    QJM; 2004 Nov; 97(11):705-16. PubMed ID: 15496527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of single factor deficiencies: a case study approach.
    Marques MB
    Clin Lab Sci; 2003; 16(2):120-2. PubMed ID: 12757193
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current status and trends in blood biologicals].
    Wang Z; Zhao X; Lv M; Zhang J
    Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):730-46. PubMed ID: 21845840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of recombinant coagulation proteins.
    Vehar GA
    Ann N Y Acad Sci; 1987; 509():82-8. PubMed ID: 3122622
    [No Abstract]   [Full Text] [Related]  

  • 19. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease.
    Mazurier C
    Semin Thromb Hemost; 2006 Jul; 32(5):529-36. PubMed ID: 16862527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Back to the future: a recent history of haemophilia treatment.
    Mannucci PM
    Haemophilia; 2008 Jul; 14 Suppl 3():10-8. PubMed ID: 18510516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.